---
title: "Telomir Reports Peer-Reviewed Preclinical Telomir-Zn Data Showing Dose-Dependent Survival & Reduced Hepatic Copper"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287061178.md"
description: "Telomir reported peer-reviewed preclinical data indicating that Telomir-Zn improves survival and reduces hepatic copper in a Wilson’s disease model. Key findings include reduced copper-driven ROS amplification, lower liver injury biomarkers, and improved locomotor performance in zebrafish. The company plans to continue its Wilson’s disease program and advance its Telomir-1 TNBC program toward Phase 1/2 clinical initiation."
datetime: "2026-05-20T12:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287061178.md)
  - [en](https://longbridge.com/en/news/287061178.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287061178.md)
---

# Telomir Reports Peer-Reviewed Preclinical Telomir-Zn Data Showing Dose-Dependent Survival & Reduced Hepatic Copper

**Telomir reported peer-reviewed preclinical data showing Telomir‑Zn produced dose-dependent survival improvements and reduced hepatic copper and liver injury markers in a Wilson’s disease model.**

**Key Highlights:**

-   Publication in Advances in Redox Research reports Telomir‑Zn reduced copper-driven ROS amplification and intracellular Ca2+ dysregulation.
-   Telomir‑Zn reduced hepatic copper accumulation and lowered liver injury biomarkers including ALT, AST, and bilirubin.
-   Preclinical results showed improved locomotor performance, reduced tissue degeneration, and dose-dependent survival benefits in a zebrafish model.
-   Findings support intracellular copper modulation as a mechanism relevant to oxidative stress and mitochondrial injury pathways.
-   Company will continue evaluating the Wilson’s disease program while advancing its Telomir‑1 TNBC program toward Phase 1/2 clinical initiation.

Original SEC Filing: Telomir Pharmaceuticals, Inc. \[ TELO \] - 8-K - May. 20, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [TELO.US](https://longbridge.com/en/quote/TELO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)
- [06:57 ETBridge to Life presenta nuevos datos en ILTS 2026 sobre HOPE con VitaSmart™](https://longbridge.com/en/news/285927884.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)